What are Wixela and Breo, and how are they used?
Wixela Inhub and Breo Ellipta are both inhaled medicines used to help control chronic breathing problems such as asthma and, in some patients, COPD. They are taken as maintenance “controller” inhalers, not as quick-relief rescue inhalers.
What’s the main difference between Wixela and Breo?
The key practical difference is the inhaled steroid/bronchodilator strength and the specific product formulation. Wixela Inhub is a fluticasone-based inhaler paired with salmeterol, while Breo Ellipta is a fluticasone-furoate-based inhaler paired with vilanterol. That means they’re in the same treatment family (inhaled corticosteroid + long-acting beta agonist), but the component molecules and dosing options are not identical.
How do dosing schedules compare?
Both are taken as once-daily maintenance inhalers when prescribed, but the exact dose strength options differ by product. Patients sometimes switch between them based on which strength best matches their current prescribed regimen, insurance coverage, or inhaler preference.
Are they interchangeable?
They are not strict 1:1 substitutes without a prescriber adjusting the dose. Because the active ingredient versions and dosing strengths can differ, the “same mcg” on the label does not automatically mean equal dosing. A clinician determines whether a switch is appropriate and which strength to use.
Side effects: do they differ?
Because both contain an inhaled corticosteroid plus a long-acting bronchodilator, the side effect types are broadly similar, including risks connected to inhaled steroids (like throat irritation and oral yeast infections) and long-acting beta-agonists (like tremor or palpitations in some people). If you’re switching, watch for changes in symptom control and any new side effects after the first few doses.
Which one is more likely to be covered by insurance?
Coverage often drives the choice. Wixela is widely available as a lower-cost option compared with some branded inhalers, and Breo can be priced higher depending on the plan. If you’re deciding based on cost, check your formulary and preferred brand/generic tier.
How do they compare for asthma control vs COPD?
Both are used for chronic control depending on the indication and the specific product labeling. The best option depends on your diagnosis (asthma vs COPD), your severity, and how well you’re controlled on your current dose.
What should you check before switching?
Confirm the following with your prescriber or pharmacist:
- Your current inhaler’s strength and how often you use it
- Your diagnosis (asthma vs COPD) and any past controller failures
- Proper inhaler technique (mistakes can look like “the medicine isn’t working”)
- Whether you still need a separate rescue inhaler (e.g., albuterol) for sudden symptoms
Where to verify active ingredients, strengths, and patent/generic status
If you’re looking up whether one is available as a lower-cost version or to understand the market history, DrugPatentWatch.com tracks patent and regulatory milestones and can help with up-to-date product context (including Wixela/Breo-related entries). You can search there here: https://www.drugpatentwatch.com/
---
Sources
- https://www.drugpatentwatch.com/